 |
| Anno II | Numero 10 | Febbraio 2017 |
| Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
PD-1/PD-L1 blockade in renal cell cancer |
| Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for … |
| Continua a leggere |
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial |
| Few effective treatments exist for patients with advanced urothelial carcinoma that has progressed after platinum-based chemotherapy. We assessed the activity and safety of nivolumab in patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after previous platinum-based chemotherapy. In this phase 1/2, multicentre, open-label study, we enrolled patients (age ≥18 years) with urothelial carcinoma of the renal pelvis, ureter, bladder, or … |
| Continua a leggere |
| PD-L1 expression in papillary renal cell carcinoma |
| The immune escape or tolerance of cancer cells is considered to be closely involved in cancer progression. Programmed death-1 (PD-1) is an inhibitory receptor expressed on activating T cells, and several types of cancer cells were found to express PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2). In the present study, we investigated PD-L1/2 expression in papillary renal cell carcinoma (pRCC). We found PD-L1 expression in 29 of 102 cases, but no PD-L2 expression was seen. PD-L1 expression was … |
| Continua a leggere |
| Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer |
| Renal cell carcinoma (RCC) historically has had limited treatment options in the metastatic setting but in the last decade, a significant arsenal of new therapies has emerged. Specifically, targeted anti-angiogenic therapies through vascular endothelial growth factor (VEGF) inhibition and immunotherapy through PD-1 inhibition have become the foundation of metastatic RCC treatment increasing not only progression-free survival but also an improved overall survival with improved toxicity profiles … |
| Continua a leggere |
| Immune checkpoint inhibitors renal side effects and management |
| The choice of immunotherapy in the treatment of cancer has improved the prognosis of many patients affected by various malignancies. The high expectations foreseen with immunotherapy have led to fast approvals despite the incomplete understanding of the toxicity profiles in the different organs, including the kidneys. The high prevalence of chronic kidney disease in cancer patients complicates the issue further and requires a better knowledge of the renal safety profile to ensure an optimal safe … |
| Continua a leggere |
| Appuntamenti AIOM |
L’integrazione dell’Oncologia con le Cure Palliative nel Paziente Oncologico in Fase Avanzata |
| Parma, 24 febbraio 2017 |
| Cancer Immunotherapy in a Real Life Context |
| Chieti, 3 marzo 2017 |
| AIOM Post ASCO GU Review UPDATES and NEWS from the Genitourinary Cancers Symposium in Orlando, FL, USA |
| Milano, 3 marzo 2017 |
| Workshop: Il Governo dell’Innovazione Farmaceutica Modelli di Gestione Sostenibile dei Farmaci Oncologici Innovativi ad Alto Costo |
| Milano, 10 marzo 2017 |
| pd-L1: un Riferimento Emergente nell’Immuno-Oncologia |
| Bari, 18 marzo 2017 Napoli, 23 marzo 2017 Aci Castello (CT), 25 marzo 2017 Parma, 12 aprile 2017 |
| Immunoterapia nei Tumori del Polmone e dell’Urotelio A che punto siamo? |
| Roma, 27 – 28 marzo 2017 |
| La Sostenibilità Futura del Servizio Sanitario: Possibili Strategie e Sinergie |
| Firenze, 31 marzo 2017 |
| Conferenza Nazionale CIPOMO La gestione del rischio in oncologia tra sicurezza e qualità |
| Ascoli Piceno, 31 marzo – 1 aprile 2017 |
| Workshop Immuno-Oncologia |
| Padova, 7 – 8 aprile 2017 |
| DOMINO Workshop DecisiOn Making IN Oncology |
| Milano, 12 aprile 2017 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo incondizionato di  |